Pravastatin protection from cold stress in myocardium of rats

Japanese Heart Journal

Volumn 44, Issue 2, 2003, Pages 243-255

  Bombig, Maria Teresa Nogueira ^a,c   Ferreira, Celso ^a   Mora, Osvaldo ^a   Soares, Joaquim Domingos ^a,b   Póvoa, Rui ^a   Filho, Braulio Luna ^a   De Jesus Simões, Manoel ^a   Filho, Celso Ferreira ^a   Murad, Neif ^a   Costa, Andrea ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Universidade de Alfenas   (Brazil)

^c NONE   (Brazil)

Author keywords

Cardiac mitochondria; Cold stress; Pravastatin

Indexed keywords

PRAVASTATIN; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; COLD STRESS; CONTROLLED STUDY; DRUG DOSE REGIMEN; ELECTRON MICROSCOPY; HEART LEFT VENTRICLE; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; ANIMAL; COLD; DRUG EFFECT; HEART; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; COLD; HEART; MICROSCOPY, ELECTRON; MITOCHONDRIA, HEART; MYOCARDIUM; MYOCYTES, CARDIAC; PRAVASTATIN; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 0038528160     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.44.243     Document Type: Article

References (51)

1. Selye H. The evolution of the stress concept. Am Sci 1973; 61: 692-9.
2. Selye H. Syndrome produced by diverse nocious agents. Nature 1936; 138: 32.
3. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason J (ed). Handbook of Life Stress, Cognition and Health, New York, John Wiley & Sons, 1988: 629-49.
4. McEwen B. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338: 171-9.
5. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Research 2000; 886: 172-89.
6. Poche R, Mattos CMM, Rembarz HW, Stoepel K. Uber das Mitochondrien: myofibrillen in den Herznuskelzellen der ratte bvei druck-hypertrophie des herzens. Virchows Arch Pathol Anat 1968; 344: 100-10.
7. Simon DK, Johns DR. Mitochondrial disorders: clinical and genetic features. Annu Rev Med 1999; 50: 111-27.
8. Borrotchin L, Lopes AC, Mora OA, Simões MJ, Ferreira C, Wafae N. Aspectos ultra-estruturais dos cardiomiócitos atriais de ratos albinos submetidos à ação do frio. Arq Bras Cardiol 1989; 53: 19-22.
9. Ferrans VJ, Roberts WC. Myocardial ultrastructure in acute chronic hypoxia. Cardiology 1971; 56: 144-60.
10. Robbins SL, Cotran RS, Kumar V, Collins T. Cell injury and cell death. In: Robbins, editor. Pathologic Basis of Diseases. Philadelphia: Saunders, 6th ed, 1999; 1: 1-30.
11. West of Scotland Coronary Prevention Study Group-Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. For the Cholesterol and Recurrent Events Trial Investigators (CARE). N Engl J Med 1996; 335: 1001-9.
13. Jukema JW, Bruschke AVG, Van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
14. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419-25.
15. Siegel S. Estadistica no paramétrica aplicada a las ciências de la conducta. México, Trillas, 1975; 350.
16. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973; 503.
17. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons, 1986; 432.
18. Alberts AW. Effects of HMG-CoA reductase inhibitors on cholesterol synthesis. Drug Invest. 1990; 2: 9-17.
19. Scandinavian Sinvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-9.
20. Waters D, Higginson L, Gladstone P, et al. The CCAIT study group. Effects of monotherapy with HMG CoA reductase inhibitors on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-68.
21. Tonkin A. Management for the long-term intervention with pravastatin in ischemic disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: C10712.
22. Salonen R, Myyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76: C34-9.
23. Blankenhorn D H, Azen SP, Kramsch DM, et al. Coronary angiography changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-76.
24. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
25. Vos J, De Feyter PJ, Simoons ML, Tyssen JG, Deckers JW. Retardation and arrest of progression or regression of coronary artery disease: a review. Prog Cardiovasc Dis 1993; 35: 435-54.
26. Waters D. Plaque stabilization. A mechanism for the beneficial effect or lipid-lowering therapies in angiography studies. Prog Cardiovasc Dis 1994; 37: 107-20.
27. Takahashi M, Yui Y, Yasumoto H, et al. Lipoproteins are inhibitors of endothelium dependent relaxation of rabbit aorta. Am J Physiol 1990; 258: H1-8.
28. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500.
29. Anderson TJ, Meredith IT, Yeung AC; Frei B, Selwin AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93.
30. Treasure CB, Klein JL, Weintrau WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
31. Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol 1997; 30: 325-33.
32. Gould KL, Martucci JP, Goldberg DI, et al. Short term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential nonivasive marker of healing coronary endothelium. Circulation 1994; 89: 1530-8.
33. Mostaza JM, Del Valle GMM, Gallardo F, et al. Incremento de la perfusion miocardica durante el tratamiento hipolipemiante en pacientes con cardiopatia isquemica. Rev Esp Cardiol 1996; 49: 669-74.
34. Van Boven AJ, Jukema JW, Zwinderman AH, Crinjs HJGM, Lie KI, Bruschke AVG. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503-5.
35. Vita JA, Treasure CB, Nabel EG, et al. The coronary vasomotor response to acetylcholine relates risk factors for coronary artery disease. Circulation 1990; 81:491-7.
36. Zeiher AM, Drexler H, Saurbier B, Just H. Effects of age, atherosclerosis, hypercholesterolemia and hypertension: endothelium-mediated coronary blood flow modulation in humans. J Clin Invest 1993; 92: 652-62.
37. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121: 1600-8.
38. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
39. Hayoz D, Weber R, Rutschman B, et al. Postischemic blood flow response in hypercholesterolemic patients. Hypertension 1995; 26: 497-502.
40. Diaz MN, Frei B, Vita JA, Keaney Jr JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16.
41. 2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759-64.
42. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 1232: 225-33.
43. Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br J Clin Pharmacol 1994; 38: 513-9.
44. Ribeiro Jorge PA, Osaki R, Metze. Effects of sinvastatin and pravastatin on endothelium dependent relaxation in hypercholesterolemic rabbits. Exp Tox Pathol 1994; 46: 465-9.
45. Kreuzer J, Watson L, Herdegen T, Loebe M, Wende P, Kubler K. Effects of HMG-CoA reductase inhibition on PDGF and angiotensin II-mediated signal transduction: suppression of c-jun e c-fos in human smooth muscle cells in vitro. Eur J Med Res 1999; 4: 135-43.
46. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 2000; 86: 514-8.
47. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
48. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-41.
49. Jay MT, Chirico S, Siow RCM, et al. Modulation of vascular tone by low-density lipoproteins: effects on Larginine transport and nitric oxide synthesis. Exp Physiol 1997; 82: 349-60.
50. Pritchard KA Fr, Groszek L, Smalley DM, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510-8.
51. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 95: 187-94.